FTC OKs $500M Valeant-PreCision Deal With Acne Drug Sales

The Federal Trade Commission agreed Thursday to sign off on Valeant Pharmaceutical International Inc.'s $500 million acquisition of PreCision Dermatology Inc. on the condition that the companies sell the rights to...

Already a subscriber? Click here to view full article